A narrative review of applications and enhancements of ChatGPT in respiratory medicine

Clinical eHealth Pub Date : 2024-12-01 DOI:10.1016/j.ceh.2024.12.006

Jun Qi Lin , Zi Xuan Hua , Liu Zhang , Ying Ni Lin , Yong Jie Ding , Xi Xi Chen , Shi Qi Li , Yi Wang , Qing Yun Li

{"title":"A narrative review of applications and enhancements of ChatGPT in respiratory medicine","authors":"Jun Qi Lin , Zi Xuan Hua , Liu Zhang , Ying Ni Lin , Yong Jie Ding , Xi Xi Chen , Shi Qi Li , Yi Wang , Qing Yun Li","doi":"10.1016/j.ceh.2024.12.006","DOIUrl":null,"url":null,"abstract":"<div><div>ChatGPT, a chatbot program pioneered by OpenAI and launched on 2022, stands alongside other notable large language models (LLMs) such as Google’s Bard Model and Baidu’s ERNIE Bot Model. These AI-powered tools have become integral to daily life, exerting considerable influence. Recently, AI’s medical applications gain traction as momentum grows. Meanwhile. chronic respiratory diseases pose a substantial global health burden, affecting nearly 550 million people in 2017, an increase of 39.8% compared to 1990. They remain a leading cause of death and disability worldwide, second only to cardiovascular diseases and cancer. The respiratory field grapples with unmet needs like antibiotic and anti-tuberculosis drug resistance, respiratory epidemics, and high prevalence of lung tumors, etc. Although the utilization of ChatGPT in medicine has been actively explored, its application in respiratory medicine remains in the early stages. In this context, we outline ChatGPT’s current respiratory medicine applications, address potential limitations, and envision future avenues for its advancement and development.</div></div>","PeriodicalId":100268,"journal":{"name":"Clinical eHealth","volume":"7 ","pages":"Pages 200-206"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical eHealth","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2588914124000194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

ChatGPT, a chatbot program pioneered by OpenAI and launched on 2022, stands alongside other notable large language models (LLMs) such as Google’s Bard Model and Baidu’s ERNIE Bot Model. These AI-powered tools have become integral to daily life, exerting considerable influence. Recently, AI’s medical applications gain traction as momentum grows. Meanwhile. chronic respiratory diseases pose a substantial global health burden, affecting nearly 550 million people in 2017, an increase of 39.8% compared to 1990. They remain a leading cause of death and disability worldwide, second only to cardiovascular diseases and cancer. The respiratory field grapples with unmet needs like antibiotic and anti-tuberculosis drug resistance, respiratory epidemics, and high prevalence of lung tumors, etc. Although the utilization of ChatGPT in medicine has been actively explored, its application in respiratory medicine remains in the early stages. In this context, we outline ChatGPT’s current respiratory medicine applications, address potential limitations, and envision future avenues for its advancement and development.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical eHealth

CiteScore

8.10

自引率

0.00%

发文量